drug
prizloncabtagene autoleucel
Phase 2updated 3mo agoby Janssen Biotech Inc
Phase 2community read0 votes
indications
indications
DLBCL
all catalysts(0)
nothing on the calendar yet
Trials studying prizloncabtagene autoleucel
- phase2A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
- phase2A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
- phase1A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma
- phase1A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma
- phase1A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects
- phase1A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma
News(1)
- J&J hands lymphoma bispecific CAR T back to AbelZetaJohnson & Johnson secured rights to prizlon-cel in 2023 for $245 million upfront. The asset in June last year showed a 100% response rate as a second-line option in a Phase 1b study for 10 patients…biospace · 3d ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that